228 related articles for article (PubMed ID: 38037728)
1. Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022.
Chatzilena A; Hyams C; Challen R; Marlow R; King J; Adegbite D; Kinney J; Clout M; Maskell N; Oliver J; Finn A; Danon L;
Euro Surveill; 2023 Nov; 28(48):. PubMed ID: 38037728
[TBL] [Abstract][Full Text] [Related]
2. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
Kirsebom FCM; Andrews N; Stowe J; Ramsay M; Lopez Bernal J
Lancet Infect Dis; 2023 Nov; 23(11):1235-1243. PubMed ID: 37453440
[TBL] [Abstract][Full Text] [Related]
3. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
4. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M
Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877
[TBL] [Abstract][Full Text] [Related]
5. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
Sane Schepisi M
Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
[TBL] [Abstract][Full Text] [Related]
7. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
Surie D; DeCuir J; Zhu Y; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Ali H; Taghizadeh L; Gong MN; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Columbus C; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Hart KW; Swan SA; Lewis NM; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1625-1630. PubMed ID: 36580424
[TBL] [Abstract][Full Text] [Related]
8. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
MMWR Morb Mortal Wkly Rep; 2023 Mar; 71(53):1637-1646. PubMed ID: 36921274
[TBL] [Abstract][Full Text] [Related]
9. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1616-1624. PubMed ID: 36580430
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.
Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Meijerink H; Ljung R; Hviid A
BMJ; 2023 Jul; 382():e075286. PubMed ID: 37491022
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Wang LF; Ren EC; Lye DC; Tan KB
Lancet Infect Dis; 2023 Dec; 23(12):1343-1348. PubMed ID: 37543042
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
14. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States.
Tseng HF; Ackerson BK; Sy LS; Tubert JE; Luo Y; Qiu S; Lee GS; Bruxvoort KJ; Ku JH; Florea A; Takhar HS; Bathala R; Zhou CK; Esposito DB; Marks MA; Anderson EJ; Talarico CA; Qian L
Nat Commun; 2023 Sep; 14(1):5851. PubMed ID: 37730701
[TBL] [Abstract][Full Text] [Related]
15. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods.
Ciesla AA; Wiegand RE; Smith ZR; Britton A; Fleming-Dutra KE; Miller J; Accorsi EK; Verani JR; Shang N; Derado G; Pilishvili T; Link-Gelles R
Open Forum Infect Dis; 2023 May; 10(5):ofad187. PubMed ID: 37213428
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
Ackerson BK; Bruxvoort KJ; Qian L; Sy LS; Qiu S; Tubert JE; Lee GS; Ku JH; Florea A; Luo Y; Bathala R; Stern J; Choi SK; Takhar HS; Aragones M; Marks MA; Anderson EJ; Zhou CK; Sun T; Talarico CA; Tseng HF
Hum Vaccin Immunother; 2024 Dec; 20(1):2335052. PubMed ID: 38575149
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
Song S; Madewell ZJ; Liu M; Miao Y; Xiang S; Huo Y; Sarkar S; Chowdhury A; Longini IM; Yang Y
Vaccine; 2024 May; 42(15):3389-3396. PubMed ID: 38653679
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
